Enhanced Scar Reduction With Triamcinolone Acetonide and Botulinum Toxin A Combination Therapy Compared to Botulinum Toxin A Monotherapy: A Translational Pilot Study
Aesthetic Surgery Journal · 2025
DOI: 10.1093/asj/sjaf094 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Aesthetic Surgery Journal, 2025. Verfasst von Shu-Hung Huang und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Triamcinolone Acetonide, Cicatrix, Hypertrophic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Science and Technology Council, Kaohsiung Medical University Hospital, Kaohsiung Municipal Siaogang Hospital.
Abstract (Originalsprache)
Background
The efficacy of combining triamcinolone acetonide (TAC) and botulinum toxin type A (BTX-A) to treat hypertrophic scars and keloids remains unclear.
Objectives
This pilot study aimed to compare the clinical efficacy of BTX-A monotherapy and TAC + BTX-A combination therapy in improving scar conditions and to investigate potential mechanisms with a rat burn scar model.
Methods
This study was conducted between March 2022 and December 2024. Each patient's scar was randomly divided into 2 equal parts, with 1 part receiving TAC + BTX-A and the other BTX-A alone for 3 sessions at 4-week intervals. Scar thickness was measured with calipers, and the Vancouver Scar Scale (VSS) was administered to assess scar condition. Pain and pruritus were evaluated with a numeric rating scale (NRS) and visual analog scale (VAS), respectively, before each intervention (V1, V2, V3) and 4 weeks after the last session (V4). In the animal study, rats with burn scars were assigned to 5 groups: sham, untreated burn, TAC, BTX-A, and TAC + BTX-A. Scar thickness and expressions of alpha smooth muscle actin (α-SMA), transforming growth factor beta (TGF-β), connective tissue growth factor (CTGF), collagen I/III, laminin, and fibronectin were analyzed histologically.
Results
Clinically, both therapies reduced scar thickness, VSS, NRS, and VAS scores. However, combination therapy showed superior reductions in scar thickness (V2-V4) and VSS scores (V3, V4) compared to BTX-A monotherapy. No significant differences were observed in NRS and VAS scores. The animal study confirmed that combination therapy more effectively reduced scar thickness, TGF-β and CTGF levels, and the collagen I/III ratio, and increased the laminin/fibronectin ratio.
Conclusions
TAC + BTX-A combination therapy enhances scar reduction by more effectively suppressing fibroblast proliferation and activation through TGF-β and CTGF downregulation, promoting scar remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Shu-Hung Huang, Sheng-Hua Wu
Förderung
- National Science and Technology Council
- Kaohsiung Medical University Hospital
- Kaohsiung Municipal Siaogang Hospital
- Childhood Burn Foundation of the Republic of China
Zitieren
APA
Huang, S. H., Wang, W. C., Chuang, H. Y., Yang, S. M., Yang, S. Y., & Wu, S. H. (2025). Enhanced Scar Reduction With Triamcinolone Acetonide and Botulinum Toxin A Combination Therapy Compared to Botulinum Toxin A Monotherapy: A Translational Pilot Study. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjaf094
Vancouver
Huang SH, Wang WC, Chuang HY, Yang SM, Yang SY, Wu SH. Enhanced Scar Reduction With Triamcinolone Acetonide and Botulinum Toxin A Combination Therapy Compared to Botulinum Toxin A Monotherapy: A Translational Pilot Study. Aesthetic Surgery Journal. 2025. doi:10.1093/asj/sjaf094
BibTeX
@article{Huang2025,
author = {Huang, Shu-Hung and Wang, Wen-Chin and Chuang, Hui-Yu and Yang, Shih-Ming and Yang, Shang-Yu and Wu, Sheng-Hua},
title = {Enhanced Scar Reduction With Triamcinolone Acetonide and Botulinum Toxin A Combination Therapy Compared to Botulinum Toxin A Monotherapy: A Translational Pilot Study},
journal = {Aesthetic Surgery Journal},
year = {2025},
doi = {10.1093/asj/sjaf094}
}
EUVIMED